Skip to main content
Inhibikase Therapeutics, Inc. logo

Inhibikase Therapeutics, Inc. — Investor Relations & Filings

Ticker · IKT ISIN · US45719W2052 LEI · 549300066CFEWOA17F12 US Manufacturing
Filings indexed 331 across all filing types
Latest filing 2026-05-12 Interim / Quarterly Rep…
Country US United States of America
Listing US IKT

About Inhibikase Therapeutics, Inc.

https://www.inhibikase.com/

Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company that develops small molecule kinase inhibitor therapeutics. The company's primary focus is on creating treatments for neurodegenerative diseases and rare cardiopulmonary conditions. Its pipeline includes IkT-148009, a c-Abl protein kinase inhibitor in clinical development for Parkinson's disease and related disorders. Additionally, the company is advancing its drug candidate IKT-001 for the treatment of pulmonary arterial hypertension (PAH).

Recent filings

Filing Released Lang Actions
10-Q - Inhibikase Therapeutics, Inc. (0001750149) (Filer)
Interim / Quarterly Report Q1 2026
2026-05-12 English
8-K - Inhibikase Therapeutics, Inc. (0001750149) (Filer)
Regulatory Filings
2026-05-12 English
8-K - Inhibikase Therapeutics, Inc. (0001750149) (Filer)
Regulatory Filings
2026-04-07 English
8-K - Inhibikase Therapeutics, Inc. (0001750149) (Filer)
Regulatory Filings
2026-03-26 English
4 - INHIBIKASE THERAPEUTICS, INC. (0001750149) (Filer)
Director's Dealing
2026-02-25 English
4 - INHIBIKASE THERAPEUTICS, INC. (0001750149) (Filer)
Director's Dealing
2026-02-25 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.